Eli Lilly has launched Copellor® (Ixekizumab) in India, providing a new treatment option for adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis. Copellor® is a humanized IgG4 monoclonal antibody that specifically targets the IL-17A protein, which plays a key role in causing inflammation in psoriasis. The drug is available in a single-dose prefilled autoinjector of 80mg/ml strength.
Psoriasis is a chronic autoimmune disease that affects millions of people worldwide, including up to 3% of the Indian population. The condition is characterized by red, scaly patches on the skin, which can be painful and itchy. Copellor® provides new hope for patients who have not found relief from traditional therapies, offering the possibility of clearer skin and reduced joint pain.
Vineet Gupta, Managing Director of Eli Lilly and Company – India & India Subcontinent, said: “We are proud to offer Copellor® to patients in India, providing a new treatment option for those living with psoriasis and psoriatic arthritis. We recognize the significant impact these conditions can have on a patient’s quality of life, and we are committed to improving outcomes for patients.”
Eli Lilly’s launch of Copellor® in India offers new hope for patients living with psoriasis and psoriatic arthritis. The availability of a new treatment option is a significant milestone for patients who have struggled to find relief from their symptoms. As a company committed to improving healthcare outcomes, Eli Lilly’s launch of Copellor® reinforces their dedication to meeting the needs of patients living with chronic
